Published in J Clin Oncol on August 02, 2010
Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients. Pediatr Blood Cancer (2015) 2.88
High-dose methotrexate-induced renal dysfunction: is glucarpidase necessary for rescue? J Clin Oncol (2011) 1.17
Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients. Cancer (2012) 0.99
Glucarpidase to combat toxic levels of methotrexate in patients. Ther Clin Risk Manag (2012) 0.93
Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy. Pharmacotherapy (2013) 0.86
Challenges in implementing individualized medicine illustrated by antimetabolite therapy of childhood acute lymphoblastic leukemia. Clin Proteomics (2011) 0.82
Interleukin 18 as a marker of chronic nephropathy in children after anticancer treatment. Dis Markers (2013) 0.81
Renoprotective effects of montelukast, a cysteinyl leukotriene receptor antagonist, against methotrexate-induced kidney damage in rats. Naunyn Schmiedebergs Arch Pharmacol (2013) 0.80
Preventing and Managing Toxicities of High-Dose Methotrexate. Oncologist (2016) 0.75
CCND1 G870A polymorphism is associated with toxicity of methotrexate in childhood acute lymphoblastic leukemia. Int J Clin Exp Pathol (2015) 0.75
Glucarpidase (voraxaze), a carboxypeptidase enzyme for methotrexate toxicity. P T (2013) 0.75
Involvement of Multiple Transporters-mediated Transports in Mizoribine and Methotrexate Pharmacokinetics. Pharmaceuticals (Basel) (2012) 0.75
Recovery of methotrexate-induced anuric acute kidney injury after glucarpidase therapy. SAGE Open Med Case Rep (2017) 0.75
Understanding and managing methotrexate nephrotoxicity. Oncologist (2006) 2.52
Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2. J Natl Cancer Inst (2004) 1.62
Methotrexate: clinical pharmacology, current status and therapeutic guidelines. Cancer Treat Rev (1977) 1.46
Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction. J Clin Oncol (1997) 1.18
Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy. Oncologist (2007) 1.14
Pharmacokinetics and metabolism of the methotrexate metabolite 2, 4-diamino-N(10)-methylpteroic acid. J Pharmacol Exp Ther (2000) 1.06
Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity. Cancer (1995) 1.05
Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure. Br J Cancer (2005) 1.04
High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. Am J Med (1980) 1.02
Carboxypeptidase-G2 rescue in cancer patients with delayed methotrexate elimination after high-dose methotrexate therapy. Leuk Lymphoma (2002) 1.01
Successful carboxypeptidase G2 rescue in delayed methotrexate elimination due to renal failure. Pediatr Hematol Oncol (1996) 0.96
Severe acute toxicity associated with high-dose methotrexate (MTX) therapy: use of therapeutic drug monitoring and test-dose to guide carboxypeptidase G2 rescue and MTX continuation. Eur J Clin Pharmacol (2006) 0.96
Optimal management of methotrexate intoxication in a child with osteosarcoma. Ann Pharmacother (2004) 0.94
Thymidine requirements for the rescue of patients treated with high-dose methotrexate. Cancer Res (1980) 0.94
Early recognition of renal toxicity of high-dose methotrexate therapy: a case report. J Pediatr Hematol Oncol (2008) 0.92
Carboxypeptidase G2 rescue in delayed methotrexate elimination in renal failure. Leuk Lymphoma (2000) 0.91
Successful carboxypeptidase G2 rescue in delayed MTX-elimination due to renal failure. Pediatr Hematol Oncol (1996) 0.91
Resumption of high-dose methotrexate after methotrexate-induced nephrotoxicity and carboxypeptidase G2 use. Am J Health Syst Pharm (2007) 0.90
Methotrexate pharmacokinetics following administration of recombinant carboxypeptidase-G2 in rhesus monkeys. J Clin Oncol (1992) 0.86
Pharmacokinetics of glucarpidase in subjects with normal and impaired renal function. J Clin Pharmacol (2008) 0.86
Dihydrofolate reductase enzyme inhibition assay for plasma methotrexate determination using a 96-well microplate reader. Clin Chem (1999) 0.85
Interactions of carboxypeptidase G2 with 6S-leucovorin and 6R-leucovorin in vitro: implications for the application in case of methotrexate intoxications. Cancer Chemother Pharmacol (2004) 0.83
[Carboxypeptidase-G2 rescue of methotrexate intoxication]. Bull Cancer (1998) 0.82
Carboxypeptidase G2 rescue in a 79 year-old patient with cranial lymphoma after high-dose methotrexate induced acute renal failure. Leuk Lymphoma (1999) 0.82
Severe methotrexate toxicity precipitated by intravenous radiographic contrast. J Pediatr Hematol Oncol (2007) 0.81
[Carboxypeptidase-G2-rescue in a woman with methotrexate-induced renal failure]. Med Klin (Munich) (2000) 0.81
Delayed methotrexate clearance in a patient with sickle cell anemia and osteosarcoma. J Pediatr Hematol Oncol (1999) 0.80
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell (2007) 12.52
Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med (2010) 3.86
Automated subcellular location determination and high-throughput microscopy. Dev Cell (2007) 3.85
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol (2013) 3.70
Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials. J Clin Oncol (2014) 3.57
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol (2010) 3.43
Automated image analysis for high-content screening and analysis. J Biomol Screen (2010) 3.02
Biological imaging software tools. Nat Methods (2012) 2.91
Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials. J Natl Cancer Inst (2012) 2.78
Understanding and managing methotrexate nephrotoxicity. Oncologist (2006) 2.52
Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol (2006) 2.50
Shortening the timeline of pediatric phase I trials: the rolling six design. J Clin Oncol (2008) 2.46
Boosting accuracy of automated classification of fluorescence microscope images for location proteomics. BMC Bioinformatics (2004) 2.46
Improved recognition of figures containing fluorescence microscope images in online journal articles using graphical models. Bioinformatics (2007) 2.43
Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res (2011) 2.40
Objective clustering of proteins based on subcellular location patterns. J Biomed Biotechnol (2005) 2.37
Advances in molecular labeling, high throughput imaging and machine intelligence portend powerful functional cellular biochemistry tools. J Cell Biochem Suppl (2002) 2.14
Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions. N Engl J Med (2012) 2.08
Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol (2008) 2.06
Loss of Smad3 in acute T-cell lymphoblastic leukemia. N Engl J Med (2004) 2.05
Immunofluorescence and fluorescent-protein tagging show high correlation for protein localization in mammalian cells. Nat Methods (2013) 2.05
Automated learning of generative models for subcellular location: building blocks for systems biology. Cytometry A (2007) 2.05
Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol (2009) 1.95
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res (2006) 1.91
A framework for the automated analysis of subcellular patterns in human protein atlas images. J Proteome Res (2008) 1.91
Deformation-based nuclear morphometry: capturing nuclear shape variation in HeLa cells. Cytometry A (2008) 1.88
Determining the distribution of probes between different subcellular locations through automated unmixing of subcellular patterns. Proc Natl Acad Sci U S A (2010) 1.82
Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr Cancer Drug Targets (2003) 1.80
Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. J Clin Oncol (2003) 1.79
Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. J Clin Oncol (2008) 1.75
Randomized phase II designs. Clin Cancer Res (2009) 1.73
Automated image analysis of protein localization in budding yeast. Bioinformatics (2007) 1.69
Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416. Clin Cancer Res (2005) 1.66
Transferrin recycling and dextran transport to lysosomes is differentially affected by bafilomycin, nocodazole, and low temperature. Cell Tissue Res (2005) 1.66
High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer (2004) 1.65
Large-scale automated analysis of location patterns in randomly tagged 3T3 cells. Ann Biomed Eng (2007) 1.63
Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Pediatrics (2005) 1.62
Declining childhood and adolescent cancer mortality. Cancer (2014) 1.62
Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2. J Natl Cancer Inst (2004) 1.62
A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study. Clin Cancer Res (2007) 1.61
High-recall protein entity recognition using a dictionary. Bioinformatics (2005) 1.60
NUCLEAR SEGMENTATION IN MICROSCOPE CELL IMAGES: A HAND-SEGMENTED DATASET AND COMPARISON OF ALGORITHMS. Proc IEEE Int Symp Biomed Imaging (2009) 1.59
Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol (2011) 1.58
From quantitative microscopy to automated image understanding. J Biomed Opt (2004) 1.58
Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother (2005) 1.57
The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol (2009) 1.56
A multiresolution approach to automated classification of protein subcellular location images. BMC Bioinformatics (2007) 1.56
Automated interpretation of subcellular patterns in fluorescence microscope images for location proteomics. Cytometry A (2006) 1.53
Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia (2012) 1.49
Intrathecal mafosfamide: a preclinical pharmacology and phase I trial. J Clin Oncol (2005) 1.48
Oxaliplatin: a review of evolving concepts. Cancer Invest (2002) 1.47
A graphical model approach to automated classification of protein subcellular location patterns in multi-cell images. BMC Bioinformatics (2006) 1.47
Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. Nat Med (2013) 1.46
Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol (2011) 1.45
Novel designs and end points for phase II clinical trials. Clin Cancer Res (2009) 1.44
A generative model of microtubule distributions, and indirect estimation of its parameters from fluorescence microscopy images. Cytometry A (2010) 1.44
Object type recognition for automated analysis of protein subcellular location. IEEE Trans Image Process (2005) 1.44
Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. J Clin Oncol (2010) 1.42
Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. Arthritis Rheum (2012) 1.40
Pediatric phase I trials in oncology: an analysis of study conduct efficiency. J Clin Oncol (2005) 1.40
Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J Clin Oncol (2006) 1.40
VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nat Rev Clin Oncol (2009) 1.37
Automated interpretation of subcellular patterns from immunofluorescence microscopy. J Immunol Methods (2004) 1.37
Clinical trial design for target-based therapy. Oncologist (2002) 1.36
A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer (2008) 1.35
A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report. Clin Cancer Res (2012) 1.33
Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol (2007) 1.31
Nutlin-3 protects kidney cells during cisplatin therapy by suppressing Bax/Bak activation. J Biol Chem (2006) 1.30
A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study. Clin Cancer Res (2007) 1.29
Putting proteins on the map. Nat Biotechnol (2006) 1.29
Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). J Clin Oncol (2004) 1.29
Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432. Clin Cancer Res (2012) 1.27
Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol (2003) 1.27
Evolution of anticancer drug discovery and the role of cell-based screening. J Natl Cancer Inst (2002) 1.26
The effect of a thyroid hormone infusion on vasopressor support in critically ill children with cessation of neurologic function. Crit Care Med (2004) 1.26
Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas. Pediatr Neurol (2007) 1.25
Objective evaluation of differences in protein subcellular distribution. Traffic (2002) 1.24
Abundant anti-apoptotic BCL-2 is a molecular target in leukaemias with t(4;11) translocation. Br J Haematol (2008) 1.24
Toxicity of sunitinib plus bevacizumab in renal cell carcinoma. J Clin Oncol (2010) 1.23
Quantifying the distribution of probes between subcellular locations using unsupervised pattern unmixing. Bioinformatics (2010) 1.22
A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors. J Clin Oncol (2010) 1.22